Oren, Yaara
Tsabar, Michael http://orcid.org/0000-0001-9470-6167
Cuoco, Michael S. http://orcid.org/0000-0003-2163-5120
Amir-Zilberstein, Liat
Cabanos, Heidie F.
Hütter, Jan-Christian http://orcid.org/0000-0002-1219-4821
Hu, Bomiao
Thakore, Pratiksha I.
Tabaka, Marcin
Fulco, Charles P.
Colgan, William http://orcid.org/0000-0002-8328-4672
Cuevas, Brandon M. http://orcid.org/0000-0002-8275-8258
Hurvitz, Sara A.
Slamon, Dennis J.
Deik, Amy
Pierce, Kerry A.
Clish, Clary http://orcid.org/0000-0001-8259-9245
Hata, Aaron N. http://orcid.org/0000-0002-6127-318X
Zaganjor, Elma
Lahav, Galit
Politi, Katerina
Brugge, Joan S. http://orcid.org/0000-0002-2547-4814
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Article History
Received: 1 June 2020
Accepted: 2 July 2021
First Online: 11 August 2021
Competing interests
: A.R. is a co-founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was a scientific advisory board member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. From 1 August 2020, A.R. has been an employee of Genentech. J.S.B. is a consultant for Agios Pharmaceuticals, eFFECTOR Therapeutics, and Frontier Medicines. Y.O., A.R. and J.S.B. are inventors on US patent application 16/563,450 filed by the Broad Institute to expressed barcode libraries as described in this manuscript. C.P.F. is now an employee of Bristol Myers Squibb. K.P. is co-inventor on a patent licensed to Molecular MD for EGFR(T790M) mutation testing (through MSKCC). K.P. has received Honoraria/Consulting fees from Takeda, NCCN, Novartis, Merck, AstraZeneca, Tocagen, Maverick Therapeutics, Dynamo Therapeutics, Halda and research support from AstraZeneca, Kolltan, Roche Boehringer Ingelheim and Symphogen. A.N.H. a consultant for Nuvalent and is supported by Novartis, Pfizer, Amgen, Blueprint Medicines, Lilly, Roche/Genetech, Nuvalent, Relay Therapeutics. S.A.H. has contracted research with Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs and Lilly, and stock options in NK Max.